The Readout Loud
Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Can rewired cells cure some patients' cancer? Do biotech stocks ever go up? And why's it taking so long to get kids vaccinated for Covid-19? Immunologist Katy Rezvani of MD Anderson Cancer Center joins us to explain the massive potential of a new approach to treating wily tumors, one that repurposes human immune cells. We also discuss the latest news in the life sciences, including an interesting hire at Novartis, the pediatric Covid-19 vaccine saga, and another negative milestone for biotech.